

Original Research

A Randomized Trial of Home-Applied Dual-Light Photodynamic Therapy in Stable Chronic Periodontitis -Three-Month Interim Results

Saila Pakarinen¹, Riitta Saarela², Hanna-Mari Välimaa³, Anna-Mari Heikkinen⁴, Esko Kankuri⁵, Marja Noponen^{2,3}, Heikki Alapulli^{3,6}, Taina Tervahartiala³, Ismo Räisänen³, Timo Sorsa^{3,7}, Tommi Pätilä⁸

¹ Metropolia University of Applied Sciences, Helsinki, Finland mailto: saila.pakarinen@metropoli.fi

² Department of Oral Health, Health and Social Services, Helsinki City, Finland: <mailto:riitta.saarela@hel.fi>; marja.noponen@hel.fi

³ Department of Oral and Maxillofacial Diseases, Faculty of Medicine, University of Helsinki, and Helsinki University Hospital, 00290 Helsinki, Finland; <mailto:ismo.raisanen@helsinki.fi> (IR); timo.sorsa@helsinki.fi (TS); hannamari.valimaa@helsinki.fi (HVM); <mailto:taina.tervahartiala@helsinki.fi> (TT.)

⁴ Faculty of Medicine and Health Technology, University of Tampere, City of Tampere Finland; <mailto:anna.heikkinen@tampere.fi>

⁵ Department of Pharmacology, Helsinki University, 00100 Helsinki, Finland; mailto: esko.kankuri@helsinki.fi

⁶ Department of Pediatric Dentistry, New Children's Hospital, University of Helsinki, 00290 Helsinki, Finland; <mailto:riitta.saarela@hel.fi>

⁷ Department of Oral Diseases, Karolinska Institute, 14152 Huddinge, Sweden; <mailto:timo.sorsa@ki.se>

⁸ Department of Congenital Heart Surgery and Organ Transplantation, New Children's Hospital, University of Helsinki, 00290 Helsinki, Finland; <mailto:tommi.patila@hus.fi>

* Correspondence: <mailto:tommi.patila@hus.fi>

Abstract: A single-site, randomized clinical trial was designed to determine efficacy of regular home use of Lumoral® dual-light antibacterial aPDT in periodontitis patients. For the study, 200 patients are randomized to receive non-surgical periodontal treatment (NSPT), including standardized hygiene instructions and electric toothbrush, and scaling and root planing, or NSPT with adjunctive Lumoral® treatment. A complete clinical intraoral examination is conducted in the beginning, at three months, and six months. This report presents the three-month results of the first 59 consecutive randomized subjects. At three months, bleeding on probing (BoP) was lower in the NSPT+Lumoral®-group than in the NSPT-group ($p=0.045$), and more patients in the NSPT+Lumoral®-group had their BoP below 10% (52% vs. 29%, respectively, $p=0.008$). Patients in the NSPT+Lumoral®-group improved their oral hygiene by visible-plaque-index ($p=0.0002$), while the NSPT-group showed no statistical improvement as compared to baseline. Both groups significantly reduced the number of deep periodontal pockets, but more patients with a reduction in their deep pocket number were found in the NSPT+Lumoral® group (92% vs. 63%, $p=0.01$). Patients whose number of deep pockets were reduced by 50% or more were also more frequent in the NSPT+Lumoral®-group (70% vs. 33%, $p=0.01$). Patients with initially less than 10 deep pockets had fewer deep pockets at three-month follow-up in the Lumoral® group ($p=0.02$). In conclusion, adjunctive use of Lumoral® in NSPT results in improved treatment outcomes at three months post-therapy.

Keywords: antibacterial photodynamic therapy; Oral hygiene; Periodontitis

1. Introduction

Periodontitis is a chronic inflammatory condition of the attachment and supporting tissues of the teeth. The subgingival microbiota and the host's immune system are the most critical factors in its generation mechanism. The disease leads to irreversible destruction of soft and hard tissue in the periodontium [1].

Antibacterial photodynamic therapy (aPDT) and antibacterial blue light (aBL) have emerged as solutions for attacking dental biofilm [2-5]. APDT is an effective antibacterial tool, but investigations of its benefit in periodontitis care have generally been disappointing [6]. However, not surprisingly, because in most studies, the treatment has been applied sparsely, actually, in most studies only once or twice [7,8]. The treatment has appeared more effective in studies which have reported repetitive aPDT treatment [9-11]. Thus, the frequency of treatment can have a significant effect on the response.

Dual-light therapy is a combined application of aPDT and aBL, and it has shown significant antibacterial efficacy in biofilms and a reduction in dental plaque development [12-14,9]. Lumoral® is a novel CE-marked medical device which provides simultaneous 405 nm aBL and 810 nm near-infrared (NIR) LED light in a mouthguard form. With indocyanine green (ICG) mouth rinse, Lumorinse® (Koite Health LTD, Espoo, Finland), the product offers simultaneous aBL and aPDT action. Selective adherence of ICG to plaque and bacteria leads to targeted antibacterial activity at the dental plaque [12,13]. In regular home use, the dual-light treatment by Lumoral® reduced inflammation and inflammatory markers in peri-implant disease and has shown benefits when used to support oral hygiene at home [9,15].

This clinical study was designed for the evaluation of effectiveness of home-applied dual-light aPDT on periodontal disease symptoms and clinical appearance. We hypothesized that when added to non-surgical periodontal treatment (NSPT), regular use of potent antimicrobial treatment would reduce the microbial burden on the gingival tissue. In addition, the regularly applied near-infrared light portion in the dual-light might have an additional photobiomodulation therapy (PBMT) effect on periodontal tissues. Reduction of gingival inflammation measured by bleeding on probing (BoP) was the primary outcome [16].

Since this is the first large clinical trial on continuous, repetitive aPDT treatment applied at home, we performed an interim analysis to determine the clinical efficacy and potential adverse events. In this interim report we provide the early three-month results of an ongoing randomized, prospective, controlled clinical trial designed to evaluate the effectiveness of the Lumoral® treatment in periodontitis patients. (Clinical-Trials.gov Identifier: NCT05278416).

2. Materials and Methods

Study design

This study is a single-site, randomized clinical trial designed to determine the efficacy of the regular home use of dual-light aPDT in periodontitis patients. The study protocol was approved by the ethics committee of the Hospital District of Helsinki and Uusimaa (HUS/3089/2021) and was conducted in accordance with the ethical principles of the Declaration of Helsinki and the good clinical practice (GCP) ISO 14155 international standard. All participants provided written informed consent before enrolment. For the study, patients are randomized to receive either non-surgical periodontal treatment (NSPT) including standardized hygiene instructions and electric toothbrush, and scaling and root planing (NSPT-group), or NSPT with Lumoral® (NSPT+Lumoral®-group) treatment.

Sample size

This interim report includes 59 consecutive patients of a total of 200 patients that shall be recruited for the entire clinical trial. Table 1 shows the Consort flow diagram reporting the enrolled, treated, and evaluated patients. For the interim analysis, there were 24 patients in the NSPT+Lumoral®-group and 27 in the NSPT-group. Any subjects over

18 years old were eligible for recruitment according to the following inclusion and exclusion criteria.

Eligibility criteria for study participants

Subjects have been referred to dental hygienist treatment by dentists or through the oral health care appointment system of the City of Helsinki. Patients were recruited during their regular oral health care visits at the Metropolia University of Applied Sciences (Helsinki, Finland). Any subjects over 18 years old were eligible for recruitment according to the following inclusion and exclusion criteria.

Inclusion criteria:

- Periodontal disease stage I-III, according to criteria the American Academy of Periodontology (AAP) with at least 2 mm interdental clinical attachment level (CAL) in the site of greatest loss.
- Age of 18- 85 years
- Presence of ≥ 20 teeth
- Agreement to participate in the study and to sign a written consent form

Exclusion criteria:

- Untreated/uncontrollable diabetes mellitus (DM) with HbA1c $\geq 7\%$ and HbA1c ≥ 8 if insulin-treated DM.
- Any systemic disease (e.g., wound healing dysfunctions) that could alter the progression of periodontal disease
- Use of medicine that would affect the periodontal tissue within the last six months (antibiotics, anti-inflammatories, anticonvulsants, immunosuppressants, or calcium channel blockers, including doxycycline, bisphosphonates, and chlorhexidine)
- Periodontal treatment during the previous three months
- Allergic to photosensitizer
- Presence of significant physical limitations or restrictions that prohibit the hygiene procedures used in the study protocol
- Removable major prosthesis or major orthodontic appliance
- Current smoking or habitual use of smokeless tobacco products
- Pregnancy or lactation
- A need for hopeless tooth extraction or open cavities in need of immediate endodontic treatment

Randomization

The randomization was performed by the sponsor using a sealed envelope system. Patients were randomized in a 1:1 group assignment ratio to the NSPT + Lumoral® and NSPT groups. Envelopes were sealed, mixed thoroughly, and then numbered. The examiner received the sequentially numbered sealed randomization envelopes.

Intra-examiner reproducibility

All clinical measurements were performed by a single experienced examiner (S.P.). The examiner was calibrated at the study's beginning regarding the probing pocket depth (PPD) and clinical attachment level (CAL). Using a manual probe, the examiner examined four teeth at six sites per tooth, with 24 measuring sites of the phantom head (Frasaco GmbH, Tettnang, Germany). The recordings for PPD and CAL were performed and documented in two sessions, maximum of 48 h apart. Calibration was considered acceptable if measurements at baseline and 48 h were equal to the millimeter at $>85\%$ level.

Clinical procedure

Demographic data were recorded. At baseline and the 3-month follow-up visit, a complete clinical intraoral examination was performed, and clinical measurements, including BOP, visible plaque index (VPI) and PPD were obtained.

After baseline measurements, all patients received standard anti-infective treatment. Patients in the study group were supplied with the Lumoral® treatment device and Lumorinse® mouth rinse for home-applied dual-light aPDT. Patients in the control group did not receive any additional intervention.

Anti-infective treatment

The standard anti-infective treatment included thorough cleaning (scaling and root planing, SRP) of all pockets (≥ 4 mm) using an ultrasound instrument (NSK Varios 750 with scalper tips G6 and G9, NSK Dental, Kanuma, Japan) with water cooling or hand instruments (LM Gracey curettes, LM-Dental Instruments, Parainen, Finland) together with cleaning powder (Perio-mate with Perio-mate powder, NSK Dental, Kanuma, Japan). In the case of asthma, RDA250 Topdent pasta cleaning was used instead.

In addition to the anti-infective treatment, standard oral hygiene instructions, including the use of an electric toothbrush, interdental brush, and dental floss, were provided to all participants. All patients were provided an electric toothbrush (Jordan AS, Oslo, Norway)

Clinical measurements

All clinical measurements were recorded with the help of a graded periodontal manual probe (North Carolina 54B, Hu-Friedy Mfg. Co., LLC, Chicago, Illinois, United States) with a maximum force of 0.25 N for six sites (mesiobuccal, buccal, distobuccal, mesiolingual, lingual, distolingual) of each tooth.

BOP was assessed at six sites per tooth, based on the presence or absence of gingival bleeding within 15 seconds after gentle probing, and it was reported as the percentage (%) of sites with positive findings of full mouth. VPI was assessed of full-mouth, with a six-point dichotomous scoring as plaque "1 present" or "0 absent". VPI is presented as the percentage (%) of sites with positive findings. PPD was measured in millimeters from the gingival margin to the base of the periodontal pocket.

Dual-light aPDT treatment

The Lumoral® treatment device is a CE-marked antibacterial home-use device for the treatment and prevention of oral diseases caused by bacteria. It is used in combination with a CE-marked mouth rinse called Lumorinse®.

Patients received detailed instructions for the use of the Lumoral® treatment device and Lumorinse® mouth rinse tablets and were instructed to use the Lumoral® treatment device and follow the protocol once a day.

The Lumorinse® mouth is an effervescent tablet with a final ICG concentration of 250 µg/mL. The mouth rinse is swished for 60 s enabling ICG to adhere to dental plaque and spitted out. The light activator mouthpiece, or Lumoral® treatment device, activates the ICG simultaneously at both the lower and upper dental arches. Lumoral® has 48 LED components delivering light on both dental arches. The device provides dual-light action, where 810 nm light activates ICG adhered to the bacteria, and 405 nm aBL is absorbed by the intrinsic chromophores, mainly porphyrins, and flavins within the bacterial cell. After 10 minutes and 30 J/cm² radiant exposure, the device automatically turns off. The treatment is used in adjunct to regular dental hygiene procedures, such as toothbrushing, interdental brushing, and dental floss use.

Compliance and adverse events reporting

Patients in the study group were asked to keep a diary of the Lumoral® use and return the remaining Lumorinse® tablets at the 3-month follow-up visit to determine the total usage. A percentage of compliance was calculated by dividing the number of used tablets by the number of treatment days. They were also asked to observe and self-report any adverse effects of the Lumoral® treatment.

Statistical analysis

GraphPad software version 9.1.0 (GraphPad Software, La Jolla, CA, USA) was used to analyze the data and create the graphs. A Wilcoxon nonparametric analysis of paired groups was performed to compare the difference of continuous variables, and the Mann-Whitney test was used to compare unpaired samples. In addition, Fisher's test was used for contingency analysis for the dichotomous variables. A *p*-value less than 0.05 was considered statistically significant.

Due to the scarcity of series in repeated antibacterial PDT use in periodontitis, the study was decided to include 200 patients. The number of patients is based on previous clinical trial data of periodontal aPDT treatments that have shown to be sufficient to allow statistical calculations [17-19]. Power analysis for the interim analysis was calculated (SAS 9.4, SAS Institute, Cary, NC, USA) from the previous study design, assigning 5% for alpha errors and 20% for TYPE II errors (80% power). Using the allocation ratio of 1 and blind to the data, we assumed a mean of BOP at 0.48 ± 36 in the control group and 0.19 ± 0.22 in the treatment group. The resulting sample size of 20 subjects in each group encouraged us to analyze this cohort.

3. Results

3.1. Demographic characteristics of the patient population

Out of 110 patients who were assessed for eligibility, 59 patients were randomized. The most common reason for unwillingness to participate was the lack of commitment due to time restrictions. The most common reasons for exclusion were current smoking, uncontrolled diabetes, less than 20 remaining teeth, or the inability to understand the study protocol due to language problems. Three patients in the NSPT group and one in the NSPT + Lumoral® group did not arrive at the cut-off point at the three-month visit. Four patients in the NSPT + Lumoral® group interrupted the study. One patient experienced excess saliva secretion and vomiting reflex during device use. Two patients felt discomfort from the warmth produced by the device. One patient did not arrive at the three-month visit and was informed about the decision to discontinue the study. In the final analysis, 51 patients were included, see Table 1.

CONSORT 2010 Flow Diagram




Table 1. Flow diagram according to the CONSORT protocol.

3.1. Bleeding on probing (BOP)

At the beginning of the study, the median BOP was 23.7% (range 8.0-48.5%) in the NSPT + Lumoral® group and 26.5% (range 26.5-53.8%) in the NSPT group, with no statistical difference between the groups. Both groups showed a reduction in BOP at the three-month visit, but the BOP in the NSPT + Lumoral® group was significantly lower ($p=0.045$), with medians of 9.7% (range 2.8-34.5%) and 14.2% (range 5.6-35.9%), respectively. See Figure 1 A. In the NSPT + Lumoral® group, 54% of the patients and 22% in the NSPT group reached BOP <10% target ($p=0.02$), see Figure 1 B.




Figure 1. A. BOP (%) at the three-month visit. B. The percentage of participants with BOP <10% at the three-month visit. BOP= Bleeding on Probing, NSPT=non-surgical periodontal treatment.

3.2. Plaque index

At the beginning of the study, the median VPI in the NSPT + Lumoral® group was 16.67% (range 3.09-42.22%) and 12,25% (range 2.47-38.1) in the NSPT group, with no statistical difference between the groups. However, in the NSPT + Lumoral® group, the VPI was significantly lower at the three-month time point with a median of 10.03% (range 1.33-31.55%), while in the NSPT group, the VPI remained statistically the same with a median of 12.26% (range 3.0-34.6%). See Figure 2.




Figure 2. A. VPI (%) in the NSPT + Lumoral® group at the beginning of the study and three months. B. VPI (%) in the NSPT group at the beginning of the study and three months. VPI= visual plaque index, NSPT=non-surgical periodontal treatment.

3.3. Periodontal pockets

At the beginning of the study, the median number of deep periodontal pockets in the NSPT + Lumoral® group was 6 (range 0-29), and in the NSPT group, a median of 7 (range 1-41) with no statistical difference between the groups. Both groups showed a significantly lower number of deep pockets at the three-month visit when the median number of deep pockets in the NSPT + Lumoral® group was 3.5 (range 0-14) and in the NSPT group 5 (range 0-14). The portion of patients who reduced the number of their deep periodontal pockets was 92% in the NSPT + Lumoral® group and 63% in the NSPT group ($p=0.02$). The portion of patients who reduced the number of their deep pockets by 50% or more was 71% in the NSPT + Lumoral® group and 33% in the NSPT group ($p=0.01$). Patients with less than 10 deep pockets at the beginning had a median of 1 (range 0-8) pocket at three months in the NSPT + Lumoral® group and a median of 4 (0-9) in the NSPT group ($p=0.01$), while no statistical difference initially. At three months, four patients with no deep pockets were found in the NSPT + Lumoral® group and one in the NSPT group. See Figure 3.




Figure 3. A. Percentage of the patients who reduced the number of their deep periodontal pockets. B. Percent of population who had a reduction of 50% or more in the number of deep pockets at three months. C. Patients who had 10 pockets or less in the beginning of the study. D. The number of patients who presented no deep pockets at three months.

3.3. Compliance and adverse events

The compliance to the Lumoral® use in those who completed the three-month surveillance was a median of 88%, ranging from 24% to 100%. There were no device-related serious adverse events. Device-related adverse events included a sensation of warming or numbness in the mouth or tongue (4) and excess salivary production (2). Two patients discontinued the device use due to the sensations (7%), and two patients discontinued due to other reasons (7%).

4. Discussion

This randomized and controlled clinical study was designed to evaluate the potential clinical effects of adjunctive antibacterial dual-light in the treatment of chronic periodontitis. Here we provide interim analysis consisting of 56 patients completing the three-month follow-up. Antibacterial dual-light aPDT was administered regularly at home with a Lumoral® device as adjunctive therapy to non-surgical periodontitis treatment. Both groups received an intervention to improve oral hygiene and toothbrushes for standardized oral hygiene. Compared to baseline, adjunctive Lumoral® use at three months resulted in lower BOP than NSPT alone. Lumoral® use also resulted in a significantly larger number of patients reaching the target value of <10% BOP, or periodontal health, compared to the NSPT alone. In addition, adjunctive Lumoral® treatment improved oral hygiene, while in the NSPT group, we observed no change. As expected, both treatments led to statistically significant improvements at three months in BOP and PPD. However, additional Lumoral® treatment significantly reduced the number of deep periodontal pockets compared to the NSPT alone. In that regard, all but two, or over 9/10, of the patients in the Lumoral® group reduced the number of deep periodontal pockets, and over 2/3 of the patients in the Lumoral® group reduced the number of their deep pockets by 50% or more during the three months. In the NSPT group, less than 2/3 of patients reduced the number of deep pockets, and 1/3 of patients reduced the number of deep periodontal pockets by 50% or more. These results are in agreement with our previously reported effects of regular dual-light treatment, where a significant reduction in aMMP-8, BOP, and VPI were seen in periodontal patients with intensive, regular, up to twice daily, Lumoral® use [9]. Similarly, a recently published case report showed a significant improvement in periodontal disease status after regular Lumoral® use in a patient with difficulties in the mechanical performance of oral hygiene at home [15].

In 2020, the European Federation of Periodontology (EFP) published its S3 Level Clinical Practice Guideline (CPG) for the treatment of Stage I–III periodontitis [20]. The guideline is based on a pre-established stepwise approach to therapy. The treatment starts with behavioral changes for improved control of supragingival biofilm and gingival inflammation, including risk factor control, before heading to the supra- and subgingival instrumentation. Additionally, case to case, different types of periodontal surgical interventions and supportive periodontal care can add benefits. The protocol in the present study was designed to accommodate the guideline structure. The guidance in oral hygiene and the use of electric toothbrushes in both groups aimed to improve home treatment as much as possible. The additional cleaning of the sub- and supragingival plaque in the clinic further reduced the effect of the microbial burden on the periodontal tissues. Most patients were in maintenance therapy, with a median number of deep pockets at 6–7. Despite reasonable disease control, the significant improvement in periodontal status with adjunctive Lumoral® treatment is exciting.

The antimicrobial effect of aPDT is mainly based on the principle that visible light activates an externally applied photosensitizer, producing reactive oxygen species (ROS) that kill bacteria indiscriminately through oxidative bursts [2]. Antimicrobial blue light (aBL) is based on the same principle, but the photosensitizers of the latter process are internal molecules in bacteria such as porphyrins and flavins [3,4]. We have investigated the effect of combined aPDT and aBL against different bacterial biofilms using ICG

photosensitizer. The simultaneous application of aBL has significantly increased the bactericidal impact compared to the aPDT alone [12-14, 21]. However, the ability of the adjunctive Lumoral® treatment to provide an antibacterial effect in the periodontal pocket is not known. Although the 810 nm light has a good tissue penetration to provide transgingival light energy, the concentration of the ICG in the periodontal pocket after mouth rinsing remains questionable.

Indocyanine green (ICG) is a widely used aPDT photosensitizer in dentistry due to its low toxicity, non-ionizing properties, water solubility, and light absorption at near-infrared (NIR) wavelengths, which have good tissue penetration [22, 12]. Several studies have shown the efficacy of NIR 810 nm/ICG aPDT as an adjunctive periodontal treatment. In a recent review, Moro et al. found ICG-mediated aPDT superior to other aPDT methods [23]. In another systematic review, Bashir et al. evaluated the efficacy of adjunctive ICG-based aPDT in periodontal patients. They found a mean additional pocket depth reduction of 1.17 mm at three months and a mean additional reduction of 1.06 mm at six months compared to the SRP alone [24]. However, a general issue in adjunctive aPDT studies is the heterogeneity of the administration protocols and, maybe even more importantly, the low frequency of the treatment [25]. Multiple obstacles are likely to arise when the treatment requires repeated visits to a dentist's office where special equipment and expertise are needed. Auspiciously, rapid development in light-emitting diode (LED) technology has allowed the development of personal products for a light applications used at home. In a home setting, the aPDT treatment can be self-administered by the patients on a more regular and frequent basis. The benefits of continued use of aPDT are not evident in the current literature, and this study provides new information.

Non-surgical periodontal therapy as the standard treatment reduces the bacterial burden and microbe-induced inflammatory response, creating a favorable environment for reattachment. However, the debridement simultaneously causes tissue trauma in the inflamed periodontal tissues, where healing occurs. The dual-light aPDT promotes not only the antibacterial action to sustain the oral hygiene reached but, potentially, an effect of PBMT, possibly leading to improved wound healing. PBMT is a complex process where the photon energy is absorbed within tissues, mainly in cytochrome-c-oxidase, and leads to induced ATP production, DNA and RNA synthesis, nitric oxide production, and modification of cellular membrane activity [26]. PBMT has been most prominently used in oral mucositis and has been recognized in the treatment recommendations [27]. In a meta-analysis by Peng et al., PBMT has been declared the most effective treatment for oral mucositis, with a probability of 95.8% [28]. However, the efficacy of PBMT in periodontitis remains debatable due to the limited available literature. But, again, the treatment frequency has been low in the studies regarding adjunctive periodontal PBMT. In a systematic review of Dalvi et al., only 2 study protocols described 5-10 treatment sessions [Dalvi]. Although Lumoral® treatment can provide PBMT regularly, this study's effect of photobiomodulation in the healing process remains debatable.

5. Conclusions

These results suggest that regular adjunctive dual-light aPDT therapy applied with a Lumoral® device can effectively improve NSPT results. However, the six-month results are warranted to define the effectiveness of the treatment further.

Author Contributions: For research articles with several authors, a short paragraph specifying their individual contributions must be provided. The following statements should be used Conceptualization, SP, RS, HVM, AMH, EK, MN, HA, TT, IR, TS, and TP; methodology, SP, RS, HVM, AMH, EK, MN, HA, TT, IR, and TS; validation, TS, AMH, and SP; formal analysis, XX; investigation, SP; resources, SP, TT, IR, and TS; data curation, SP, TS; writing—original draft preparation, SP, RS, HVM, AMH, EK, MN, HA, TT, IR, and TS; writing—review and editing, SP, RS, HVM, AMH, EK, MN, HA, TT, IR, and TS; visualization, EK, IR; supervision, TS; project administration, TS; funding acquisition, TS, TP All authors have read and agreed to the published version of the manuscript.

Funding: This article received financial support from research grants from Helsinki and Uusimaa Hospital District (HUS): TYH 2022225, TYH2018229, TYH2019319, Y1014SL017, Y1014SL018, Y1014SULE1, Y2114SU010, Finnish Dental Association Apollonia, Karolinska Institutions Apollonia. Koite Health supported the expenses of the study site, Lumoral devices, and toothbrushes. The University of Helsinki provided open-access funding.

Institutional Review Board Statement: This study was conducted in accordance with the ethical principles of the Declaration of Helsinki. This study was approved by the ethics committee of the Hospital District of Helsinki and Uusimaa (HUS/3089/2021), and all participants provided written informed consent before enrolment.

Informed Consent Statement: Informed consent was obtained from all subjects involved in the study.

Data Availability Statement: The data supporting the results reported here are available from the corresponding author upon request.

Conflicts of Interest: Timo Sorsa is the inventor of the following patents: 1274,416-patent U.S. 5,652,223, 5,736,341, 5,864,632, 6,143,476, and US 2017/0023571A1 (issued June 6, 2019); WO 2018/060553 A1 (issued May 31, 2019); 10,488,415 B2, Japanese Patent 2016-554676; and South Korean patent 10-2016-7025378. Tommi Pätälä is a member of the board of Koite Health LTD. The company has filed patents P21233F100 and P22769F100 and owns trademarks related to antibacterial dual-light. Koite Health LTD develops, sells, and markets dual-light antibacterial products for the prevention and treatment of dental and periodontal infections

References

1. Sanz M, Beighton D, Curtis MA, Cury JA, Dige I, Dommisch H, Ellwood R, Giacaman RA, Herrera D, Herzberg MC, Könönen E, Marsh PD, Meyle J, Mira A, Molina A, Mombelli A, Quirynen M, Reynolds EC, Shapira L, Zaura E. Role of microbial biofilms in the maintenance of oral health and in the development of dental caries and periodontal diseases. Consensus report of group 1 of the Joint EFP/ORCA workshop on the boundaries between caries and periodontal disease. *J Clin Periodontol*. 2017 Mar;44 Suppl 18:S5-S11. doi: 10.1111/jcpe.12682. PMID: 28266109.
2. Cieplik, F.; Deng, D.; Crielaard, W.; Buchalla, W.; Hellwig, E.; Al-Ahmad, A.; Maisch, T. Antimicrobial photodynamic therapy—What we know and what we don't. *Crit. Rev. Microbiol.* 2018, 44, 571–589. <https://doi.org/10.1080/1040841X.2018.1467876>.
3. Konopka, K.; Goslinski, T. Photodynamic Therapy in Dentistry. *J. Dent. Res.* 2007, 86, 694–707. <https://doi.org/10.1177/154405910708600803>.
4. Wang, Y.; Wang, Y.; Wang, Y.; Murray, C.K.; Hamblin, M.R.; Hooper, D.C.; Dai, T. Antimicrobial blue light inactivation of pathogenic microbes: State of the art. *Drug Resist. Updat.* 2017, 33–35, 1–22. <https://doi.org/10.1016/j.drug.2017.10.002>.
5. De Sousa, D.L.; Lima, R.A.; Zanin, I.C.; Klein, M.I.; Janal, M.N.; Duarte, S. Effect of Twice-Daily Blue Light Treatment on Matrix-Rich Biofilm Development. *PLoS ONE* 2015, 10, e0131941. <https://doi.org/10.1371/journal.pone.0131941>.
6. Herrera, D. Insufficient evidence for photodynamic therapy use in periodontitis. *Evid Based Dent* 12, 46 (2011). <https://doi.org/10.1038/sj.ebd.6400791>.
7. Chambrone L, Wang HL, Romanos GE. Antimicrobial photodynamic therapy for the treatment of periodontitis and peri-implantitis: An American Academy of Periodontology best evidence review. *J Periodontol*. 2018 Jul;89(7):783-803. doi: 10.1902/jop.2017.170172. PMID: 30133749.
8. Smiley CJ, Tracy SL, Abt E, Michalowicz BS, John MT, Gunsolley J, Cobb CM, Rossmann J, Harrel SK, Forrest JL, Hujoel PP, Noraian KW, Greenwell H, Frantsve-Hawley J, Estrich C, Hanson N. Systematic review and meta-analysis on the non-surgical treatment of chronic periodontitis by means of scaling and root planing with or without adjuncts. *J Am Dent Assoc.* 2015 Jul;146(7):508-24.e5. doi: 10.1016/j.adaj.2015.01.028. PMID: 26113099.
9. Lähteenmäki H, Pätälä T, Räisänen IT, Kankuri E, Tervahartiala T, Sorsa T. Repeated Home-Applied Dual-Light Antibacterial Photodynamic Therapy Can Reduce Plaque Burden, Inflammation, and aMMP-8 in Peri-Implant Disease-A Pilot

- Study. *Curr Issues Mol Biol.* 2022 Mar 8;44(3):1273-1283. doi: 10.3390/cimb44030085. PMID: 35723308; PMCID: PMC8947626.
10. Giannelli M, Materassi F, Fossi T, Lorenzini L, Bani D. Treatment of severe periodontitis with a laser and light-emitting diode (LED) procedure adjunctive to scaling and root planing: a double-blind, randomized, single-center, split-mouth clinical trial investigating its efficacy and patient-reported outcomes at 1 year. *Lasers Med Sci.* 2018 Jul;33(5):991-1002. doi: 10.1007/s10103-018-2441-9. Epub 2018 Jan 18. PMID: 29349511.
 11. Giannelli M, Formigli L, Lorenzini L, Bani D. Efficacy of Combined Photoablative-Photodynamic Diode Laser Therapy Adjunctive to Scaling and Root Planing in Periodontitis: Randomized Split-Mouth Trial with 4-Year Follow-Up. *Photomed Laser Surg.* 2015 Sep;33(9):473-80. doi: 10.1089/pho.2015.3955. Epub 2015 Aug 3. PMID: 26237453.
 12. Nikinmaa, S.; Alapulli, H.; Auvinen, P.; Vaara, M.; Rantala, J.; Kankuri, E.; Sorsa, T.; Meurman, J.; Pätälä, T. Dual-light photodynamic therapy administered daily provides a sustained antibacterial effect on biofilm and prevents *Streptococcus mutans* adaptation. *PLoS ONE* 2020, 15, e0232775. <https://doi.org/10.1371/journal.pone.0232775>.
 13. Nikinmaa, S.; Moilanen, N.; Sorsa, T.; Rantala, J.; Alapulli, H.; Kotiranta, A.; Auvinen, P.; Kankuri, E.; Meurman, J.; Pätälä, T. Indocyanine Green-Assisted and LED-Light-Activated Antibacterial Photodynamic Therapy Reduces Dental Plaque. *Dent. J.* 2021, 9, 52. <https://doi.org/10.3390/dj9050052>.
 14. Nikinmaa, S.; Podonyi, A.; Raivio, P.; Meurman, J.; Sorsa, T.; Rantala, J.; Kankuri, E.; Tauriainen, T.; Pätälä, T. Daily Administered Dual-Light Photodynamic Therapy Provides a Sustained Antibacterial Effect on *Staphylococcus Aureus*. *Antibiot.* 2021, 10, 1240. <https://doi.org/10.3390/antibiotics10101240>.
 15. Trujillo, K.; Räisänen, I.T.; Sorsa, T.; Pätälä, T. Repeated Daily Use of Dual-Light Antibacterial Photodynamic Therapy in Periodontal Disease – A Case Report. *Dent. J.* 2022, 10, 163. <https://doi.org/10.3390/dj10090163>.
 16. Lang NP, Adler R, Joss A, Nyman S. Absence of bleeding on probing. An indicator of periodontal stability. *J Clin Periodontol.* 1990 Nov;17(10):714-21. doi: 10.1111/j.1600-051x.1990.tb01059.x. PMID: 2262585.
 17. Schär D, Ramseier CA, Eick S, Mettraux G, Salvi GE, Sculean A. Transgingival photodynamic therapy (tg-aPDT) adjunctive to subgingival mechanical instrumentation in supportive periodontal therapy. A randomized controlled clinical study. *Photodiagnosis Photodyn Ther.* 2020 Dec;32:101971. doi: 10.1016/j.pdpdt.2020.101971. Epub 2020 Aug 21. PMID: 32835882.
 18. Joshi K, Baiju CS, Khashu H, Bansal S. Clinical effectiveness of indocyanine green mediated antimicrobial photodynamic therapy as an adjunct to scaling root planing in treatment of chronic periodontitis- A randomized controlled clinical trial. *Photodiagnosis Photodyn Ther.* 2020 Mar;29:101591. doi: 10.1016/j.pdpdt.2019.101591. Epub 2019 Nov 26. PMID: 31783161.
 19. Monzavi, A.; Chinipardaz, Z.; Mousavi, M.; Fekrazad, R.; Moslemi, N.; Azaripour, A.; Bagherpasande, O.; Chiniforusha, N. Antimicrobial photodynamic therapy using diode laser activated indocyanine green as an adjunct in the treatment of chronic periodontitis: A randomized clinical trial. *Photodiagnosis and Photodynamic Therapy* 14 (2016), 93-97.
 20. Sanz M, Herrera D, Kebschull M, Chapple I, Jepsen S, Beglundh T, Sculean A, Tonetti MS; EFP Workshop Participants and Methodological Consultants. Treatment of stage I-III periodontitis-The EFP S3 level clinical practice guideline. *J Clin Periodontol.* 2020 Jul;47 Suppl 22(Suppl 22):4-60. doi: 10.1111/jcpe.13290. Erratum in: *J Clin Periodontol.* 2021 Jan;48(1):163. PMID: 32383274; PMCID: PMC7891343. Author 1, A.; Author 2, B. Title of the chapter. In Book Title, 2nd ed.; Editor 1, A., Editor 2, B., Eds.; Publisher: Publisher Location, Country, 2007; Volume 3, pp. 154–196.
 21. Hentilä, J.; Laakamaa, N.; Sorsa, T.; Meurman, J.; Välimaa, H.; Nikinmaa, S.; Kankuri, E.; Tauriainen, T.; Pätälä, T. Dual-Light Photodynamic Therapy Effectively Eliminates *Streptococcus Oral* Biofilms. *J. Pharm. Pharm. Sci.* 2021, 24, 484–487. <https://doi.org/10.18433/jpps32084>.
 22. Alander, J.T.; Kaartinen, I.; Laakso, A.; Pätälä, T.; Spillmann, T.; Tuchin, V.; Venermo, M.; Välisuo, P. A Review of Indocyanine Green Fluorescent Imaging in Surgery. *Int. J. Biomed. Imaging* 2012, 2012, 1–26. <https://doi.org/10.1155/2012/940585>.
 23. Moro MG, de Carvalho VF, Godoy-Miranda BA, Kassa CT, Horliana ACRT, Prates RA. Efficacy of antimicrobial photodynamic therapy (aPDT) for non-surgical treatment of periodontal disease: a systematic review. *Lasers Med Sci.* 2021 Oct;36(8):1573-1590. doi: 10.1007/s10103-020-03238-1. Epub 2021 Jan 12. PMID: 33438165.
 24. Bashir NZ, Singh HA, Virdee SS. Indocyanine green-mediated antimicrobial photodynamic therapy as an adjunct to periodontal therapy: a systematic review and meta-analysis. *Clin Oral Investig.* 2021 Oct;25(10):5699-5710. doi: 10.1007/s00784-021-03871-2. Epub 2021 Mar 12. PMID: 33710461; PMCID: PMC8443506.
 25. Sculean, A.; Deppe, H.; Miron, R.; Schwarz, F.; Romanos, G.; Cosgarea, R. Effectiveness of photodynamic therapy in the treatment of periodontal and peri-implant diseases. *Oral Biofilms* 2021, 29, 133–143. <https://doi.org/10.1159/000510189>.
 26. Dalvi S, Benedicenti S, Hanna R. Effectiveness of Photobiomodulation as an Adjunct to Nonsurgical Periodontal Therapy in the Management of Periodontitis- A Systematic Review of in vivo Human Studies. *Photochem Photobiol.* 2021 Mar;97(2):223-242. doi: 10.1111/php.13348. Epub 2020 Nov 12. PMID: 33098680.
 27. National Institute for Health and Care Excellence. (2018). Low-level laser therapy for preventing or treating oral mucositis caused by radiotherapy or chemotherapy. NICE Interventional procedures guidance [IPG615] <https://www.nice.org.uk/guidance/ipg615>.
 28. Peng H, Chen BB, Chen L, Chen YP, Liu X, Tang LL, Mao YP, Li WF, Zhang Y, Lin AH, Sun Y, Ma J. A network meta-analysis in comparing prophylactic treatments of radiotherapy-induced oral mucositis for patients with head and neck cancers receiving radiotherapy. *Oral Oncol.* 2017 Dec;75:89-94. doi: 10.1016/j.oraloncology.2017.11.001. Epub 2017 Nov 8. PMID: 29224830.